Blood Test Could Identify Diabetes Decades Before It Develops
By LabMedica International staff writers Posted on 22 Jul 2015 |
A small molecule circulates in the blood of people who are in the early stages of type 1 diabetes and a simple blood test could detect this biological marker years, maybe decades, before symptoms develop.
Micro ribonucleic acids (miRNAs) carry snippets of genetic information across cells, and are regularly released into the blood stream and in diabetes the levels of some of these miRNAs in the circulation changes, and a blood test could detect these variations.
An international team of scientists, led by those at the Imperial College London (UK), have been able to identify a miRNA that is linked to the pancreas. They first used a murine model to establish the techniques and then recruited individuals diagnosed with diabetes who were less than 45 years of age. The subjects studied included 45 with the genetic mutation HNF1α-MODY3, 38 with type 1 diabetes (T1D) and 58 with type 2 diabetes (T2D). There were 51 controls who were normoglycemic individuals aged 30 to 50 years.
RNA was reverse transcribed using a High Capacity cDNA Reverse Transcription kit and miRNA levels were measured using the TaqMan microRNA Assays (Applied Biosystems; Waltham, MA, USA). Quantitative polymerase chain reaction (PCR) was performed by Roche 384 real-time PCR machine and using Light Cycler 480 SYBR Green Master (Roche; Basel Switzerland).
The scientists reported that a particular molecule, called miR-375, is released by the very cells in the pancreas that produce insulin. These cells normally contain lots of miR-375, which helps to control cell growth. In T1D it is released into the bloodstream in large quantities as soon as the cells begin to die. Their results indicate that that plasma miR-375 levels do not discriminate between different forms of T2D, but may be used as an indicator of acute β-cell destruction and autoimmune diabetes.
The authors concluded that their findings are supported by higher miR-375 levels in the circulation of T1D subjects but not mature onset diabetes of the young (MODY) andT2D patients. Together, their data support an essential role for miR-375 in the maintenance of β-cell mass and provide in vivo evidence for release of miRNAs from pancreatic β-cells. The small contribution of β-cells to total plasma miR-375 levels make this miRNA an unlikely biomarker for β-cell function but suggests a utility for the detection of acute β-cell death for autoimmune diabetes. The study was published on May 28, 2015, in the Journal of Molecular Medicine.
Related Links:
Imperial College London
Applied Biosystems
Roche
Micro ribonucleic acids (miRNAs) carry snippets of genetic information across cells, and are regularly released into the blood stream and in diabetes the levels of some of these miRNAs in the circulation changes, and a blood test could detect these variations.
An international team of scientists, led by those at the Imperial College London (UK), have been able to identify a miRNA that is linked to the pancreas. They first used a murine model to establish the techniques and then recruited individuals diagnosed with diabetes who were less than 45 years of age. The subjects studied included 45 with the genetic mutation HNF1α-MODY3, 38 with type 1 diabetes (T1D) and 58 with type 2 diabetes (T2D). There were 51 controls who were normoglycemic individuals aged 30 to 50 years.
RNA was reverse transcribed using a High Capacity cDNA Reverse Transcription kit and miRNA levels were measured using the TaqMan microRNA Assays (Applied Biosystems; Waltham, MA, USA). Quantitative polymerase chain reaction (PCR) was performed by Roche 384 real-time PCR machine and using Light Cycler 480 SYBR Green Master (Roche; Basel Switzerland).
The scientists reported that a particular molecule, called miR-375, is released by the very cells in the pancreas that produce insulin. These cells normally contain lots of miR-375, which helps to control cell growth. In T1D it is released into the bloodstream in large quantities as soon as the cells begin to die. Their results indicate that that plasma miR-375 levels do not discriminate between different forms of T2D, but may be used as an indicator of acute β-cell destruction and autoimmune diabetes.
The authors concluded that their findings are supported by higher miR-375 levels in the circulation of T1D subjects but not mature onset diabetes of the young (MODY) andT2D patients. Together, their data support an essential role for miR-375 in the maintenance of β-cell mass and provide in vivo evidence for release of miRNAs from pancreatic β-cells. The small contribution of β-cells to total plasma miR-375 levels make this miRNA an unlikely biomarker for β-cell function but suggests a utility for the detection of acute β-cell death for autoimmune diabetes. The study was published on May 28, 2015, in the Journal of Molecular Medicine.
Related Links:
Imperial College London
Applied Biosystems
Roche
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer